参考文献

［1］ ZOUNGAS S, ARIMA H, GERSTEIN H C, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of inpidual participant data from randomised controlled trials [J]. Lancet Diabetes Endocrinol, 2017, 5 (6): 431-437.

［2］ ANDERS H J, HUBER T B, ISERMANN B, et al. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease [J]. Nat Rev Nephrol, 2018, 14 (6): 361-377.

［3］ SARAN R, ROBINSON B, ABBOTT K C, et al. Us renal data system 2016 annual data report: Epidemiology of kidney disease in the united states [J]. Am J Kidney Dis, 2017, 69 (3 Suppl 1): A7-A8.

［4］ JAMES M T, GRAMS M E, WOODWARD M, et al. A meta-analysis of the association of estimated gfr, albuminuria, diabetes mellitus, and hypertension with acute kidney injury [J]. Am J Kidney Dis, 2015, 66 (4): 602-612.

［5］ FEARN A, SHEERIN N S. Complement activation in progressive renal disease [J]. World J Nephrol,2015, 4 (1): 31-40.

［6］ STEFFENSEN C, PEREIRA A M, DEKKERS O M, et al. Diagnosis of endocrine disease: Prevalence of hypercortisolism in type 2 diabetes patients: A systematic review and meta-analysis [J]. Eur J Endocrinol, 2016, 175 (6): R247-R253.

［7］ LEE M Y, HSIAO P J, HUANG J C, et al. Association between metabolic syndrome and microvascular and macrovascular disease in type 2 diabetic mellitus [J]. Am J Med Sci, 2018, 355 (4): 342-349.